Corrections

Every time we published something about a clinic that was wrong, for a stretch of time, on a page you could read. Each entry says what we said, what was true, why it happened, what we changed, and whether the clinic pays us.

13 corrections, newest first. How scores are set: how we score.

MangoRx: we said Eli Lilly's lawsuit was ongoing. It settled in June 2025

Published 2026-09-17. Corrected 2026-10-26.

What we published: MangoRx's review said: "Eli Lilly has sued MangoRx, alleging its compounded oral tirzepatide product improperly copies Zepbound/Mounjaro and has not been independently tested or FDA-reviewed for safety or efficacy. MangoRx disputes the claims. Litigation was ongoing as of mid-2026." Its one-liner mentioned "active Eli Lilly litigation", its transparency note called the suit "Actively contested litigation", and its treatments listed oral tirzepatide beside oral semaglutide.
What was actually true: Mangoceuticals, the company behind MangoRx, reports in its Form 10-Q for the quarter ended March 31, 2026 (filed with the SEC on May 19, 2026): "On June 23, 2025, the Company and Eli Lilly entered into a Confidential Settlement and Mutual Release Agreement whereby both parties agreed to settle and resolve the complaint upon the Company agreeing pay Eli Lilly a total of $ 20,000 in cash (the 'Settlement Amount') and the Company agreeing to refrain from marketing and selling its Tirzepatide based 'TRIM' products on its MangoRx.com website in the future. The Company paid the Settlement Amount on June 27, 2025 and the dispute has been settled in full." On October 26, 2026 mangorx.com listed only one weight-loss product, Slim (compounded oral semaglutide), and its old tirzepatide product page returned a 404.
Why it happened: We carried the lawsuit note over from our sister site, where it was written from news coverage of the court filings in August 2026. It was never checked against the company's own filings, which had reported the settlement more than a year earlier.
How we found out: An editorial review of the legal claims on our clinic pages on October 26, 2026, which read Mangoceuticals' 10-Q on sec.gov.
What we changed: The review now says the suit settled on June 23, 2025, with the filing quoted and dated, and the one-liner no longer mentions litigation. Oral tirzepatide is removed from MangoRx's treatments, so it no longer appears in tirzepatide or oral tirzepatide filters. Scores are unchanged: transparency stays 4.0 and treatment 6.5, total 5.5/10, and the transparency and treatment notes now say the suit is settled and the tirzepatide tablets are no longer sold. Whether those two scores should change is a separate decision still to be made.
Does this clinic pay us?: Not a partner. MangoRx's affiliate program did not approve this site, it has no affiliate link here and we earn nothing from it.

MangoRx review

MangoRx: we said its price was not shown up front. Its product page shows $299 a month

Published 2026-09-17. Corrected 2026-10-26.

What we published: MangoRx's review said, under price: "Pricing is not surfaced up front on the site", and under transparency: "Pricing is not shown up front and the independent review record is sparse." The transparency score of 4.0 was explained by two flags: an SSL certificate observed expired on 22 June 2026 and Eli Lilly's lawsuit. The treatment score of 6.5 counted two molecules, oral semaglutide and oral tirzepatide.
What was actually true: On October 26, 2026 MangoRx's Slim product page (mangorx.com/products/slim) showed "Starting at $299.00/mo" and a single plan, "$299.00/ month Billed monthly. Cancel anytime."; its checkout showed "Slim $299.00/mo" and offered one option, a 30-day supply at $299 a month. The price we record, $299 a month, was right. MangoRx's weight-loss page (mangorx.com/weight-loss) said "Starting at $67 / mo" on the same day; no plan at that price exists in the checkout, so it is not a separate offer. The SSL certificate was valid on October 26, 2026, the Lilly lawsuit had settled on June 23, 2025 (see the correction of the same day about that suit), and Slim, oral semaglutide, was the only weight-loss product on sale.
Why it happened: The price notes were carried over from our sister site, where the product page returned no readable text to an automated fetch; "not surfaced up front" described what that fetch saw, not the page a visitor sees. The two transparency flags and the second molecule were not re-checked after the record was ported.
How we found out: An editorial re-read of MangoRx's pages on October 26, 2026, in a real browser, after we noticed the weight-loss page and the product page showed different prices.
What we changed: The price stays $299 a month, now recorded with its billing term, source and read date, and the review says the product page shows it up front; the $67 figure is shown as a contradiction between MangoRx's own pages, not as a price. Two scores were re-scored on the evidence: treatment 6.5 to 5.5 (one molecule by one route) and transparency 4.0 to 4.5 (the expired certificate and the open lawsuit no longer apply; the $67 versus $299 gap, the refund wording in the Terms and the missing state list still count against it). Price stays 5.5 and clinical 6.0. The total moves from 5.5 to 5.4 out of 10 and MangoRx moves from #46 to #47 of 47; TrimRx moves from #47 to #46. We also now record that MangoRx names its operator, Mangoceuticals, Inc., and its pharmacy, Epiq Scripts, LLC, in its Terms.
Does this clinic pay us?: Not a partner. MangoRx's affiliate program did not approve this site, it has no affiliate link here and we earn nothing from it.

MangoRx review

MangoRx: we said Slim was available in 39 states. Its checkout serves 26

Published 2026-09-17. Corrected 2026-10-26.

What we published: MangoRx's review and our state filter said it served 39 of 51 states and was not available in Alabama, Alaska, Arkansas, California, Kentucky, Louisiana, Michigan, Mississippi, North Dakota, South Carolina, South Dakota and Wyoming. The list had no source or read date.
What was actually true: On October 26, 2026 the checkout for Slim, MangoRx's only weight-loss product (mangorx.com/products/slim/get-started), listed 26 eligible states: Arizona, California, Colorado, Connecticut, Florida, Illinois, Indiana, Iowa, Kentucky, Maine, Michigan, Montana, Nebraska, Nevada, New Hampshire, New York, North Carolina, Ohio, Pennsylvania, South Carolina, Tennessee, Texas, Utah, Vermont, Washington and Wyoming. Five states we listed as not served (California, Kentucky, Michigan, South Carolina, Wyoming) are on that list, and 18 places we listed as served are not: Delaware, Georgia, Hawaii, Idaho, Kansas, Maryland, Massachusetts, Minnesota, Missouri, New Jersey, New Mexico, Oklahoma, Oregon, Rhode Island, Virginia, West Virginia, Wisconsin and Washington, D.C. MangoRx's general FAQ answer on shipping names 46 states and Washington, D.C. for the whole company; it is not a list for Slim.
Why it happened: The state list was carried over from our sister site without a source or a read date, and was never checked against MangoRx's own checkout for Slim.
How we found out: An editorial re-read of MangoRx's checkout on October 26, 2026, in a real browser, after we noticed that states on its eligible list were on our list of states it does not serve.
What we changed: MangoRx now shows as available in 26 of 51 (the 50 states and Washington, D.C.), with the checkout as the source and October 26, 2026 as the read date, on its review and in every place that filters clinics by state. No score changes because of this: our rubric asks whether a clinic lists the states it serves, not how many it serves, and Slim's list is still shown only inside the checkout, so the transparency score stays 4.5; its note now says where the list is.
Does this clinic pay us?: Not a partner. MangoRx's affiliate program did not approve this site, it has no affiliate link here and we earn nothing from it.

MangoRx review

MangoRx names its pharmacy; its clinical score rises from 6.0 to 6.5

Published 2026-09-17. Corrected 2026-10-26.

What we published: MangoRx's clinical score was 6.0. Its note said a physician reviews each request before fulfilment and that LegitScript certification is claimed only at the partner-pharmacy level, and the score was set as though no pharmacy was named.
What was actually true: MangoRx's Terms (mangorx.com/terms-and-conditions, read October 26, 2026) say: "MangoRx operates as a technology platform connecting users to prescription fulfillment services through Epiq Scripts, LLC pharmacy and various Medical Groups with contracted healthcare providers." The pharmacy is named; the medical groups and the clinicians are not. Its FAQ, read the same day, says visits are asynchronous or live, depending on treatment and state, within one to five business days.
Why it happened: The clinical note was carried over from our sister site, where only the pharmacy disclaimer page had been read; it names no pharmacy. The Terms were not read until October 26, 2026.
How we found out: The same October 26, 2026 re-read of MangoRx's pages that found its price and its lawsuit had moved on (see the two corrections of that day).
What we changed: Clinical 6.0 to 6.5, at the level of clinics that name one entity or offer a live visit but name no clinician and publish no follow-up schedule (Henry Meds and Zealthy, both 6.5). Price 5.5, treatment 5.5 and transparency 4.5 are unchanged. The total moves from 5.40 to 5.55, shown as 5.4 to 5.5 out of 10, and MangoRx moves from #47 to #46 of 47; TrimRx moves from #46 to #47. No other clinic moves.
Does this clinic pay us?: Not a partner. MangoRx's affiliate program did not approve this site, it has no affiliate link here and we earn nothing from it. TrimRx, which moves down one place, is not a partner either. Commission is never an input to any score.

MangoRx reviewTrimRx

Partners with an FDA warning letter now get the same links and placements as other partners

Published 2026-10-12. Corrected 2026-10-24.

What we published: From 12 October 2026 an affiliate partner with an open FDA warning letter kept its affiliate link only on its own review. In the ranking, on the homepage cards, in the clinic finder, in the sticky bar and in other clinics' Alternatives lists its row linked to its review instead, it carried no PICK badge, and the Partner offer block left out any partner with an FDA warning letter on file. Our affiliate disclosure said so.
What was actually true: This was a placement policy, not a finding about any clinic, and none of the letters has changed. We decided that a letter is something to disclose, not a reason to move a link: the letter stays on the partner's own review with its source, it still caps the partner's score, and the partner now gets the same links, placements and PICK badge as every other affiliate partner. PICK marks the commercial relationship the disclosure promises on partner links, so removing it hid that relationship.
Why it happened: An editorial decision of 12 October 2026, reversed on 24 October 2026.
How we found out: Our own review of the commercial placement rules on 24 October 2026.
What we changed: Direct Meds, SkinnyRx, Strut Health and Sprout Health now link out from the ranking and the other placements and carry PICK. Scores, ranks, the FDA notices on their reviews and the transparency caps are unchanged. Sprout Health stays out of the price ticker for a price reason, not for its letter. A few review pages held unchanged until 30 October 2026 keep the previous rule in their Partner offer block and sticky bar.
Does this clinic pay us?: Yes. All four are affiliate partners and pay us a commission on sign ups through our links.

Direct Meds review SkinnyRx review Strut Health review Sprout Health review

Oak's published price is back to $119/mo, not $89; its pricing score falls from 8.5 to 8.0

Published 2026-09-28. Corrected 2026-10-11.

What we published: Oak's review and our rankings gave its price as "from $89/mo", read from Oak's homepage on 28 September 2026, with a pricing score of 8.5 and a total of 7.2/10, #19 of 46.
What was actually true: Oak's homepage, read 11 October 2026, says "Prescription weight loss from $119/mo" and "GLP-1 Treatments for weight loss from $119/mo". Among clinics with the same all-inclusive pricing, $119 sits between Telos Rx at $99 (pricing 8.0) and FeelGood at $149 (7.5).
Why it happened: The price moved on Oak's own page after our 28 September read. Our automated spot-check saw $119 on 6 October and marked the price unverified, but the record was not corrected until a decision was made.
How we found out: The 6 October spot-check, confirmed when we read the page again on 11 October 2026.
What we changed: Price $89 -> $119; pricing 8.5 -> 8.0; total 7.2 -> 7.1; rank #19 -> #20 of 46.
Does this clinic pay us?: Oak IS an affiliate partner. We may earn a commission if you sign up through our link. This correction moves a partner's price UP and its score DOWN, from 7.2 to 7.1, and the cause is Oak's own published price, not the partnership. Commission is never an input to any score.

Oak review

Wellorithm's pricing score was set on a first-month price; re-scored on its $247 monthly rate, it moves from #1 to #4

Published 2026-09-17. Corrected 2026-10-08.

What we published: Wellorithm's pricing score was 8.0 and its total 8.3/10, #1 in our ranking. The 8.0 had been set when we read its price as "$147/mo".
What was actually true: Wellorithm's semaglutide card says "first month $147" and "Second month and on. $247" (read 6 October 2026). The rate you pay from the second month is $247. Among clinics with the same all-inclusive pricing, the closest comparisons are Noom Med ($129 to start, then $249 a month) and Direct Meds ($249 a month), both scored 5.5 on pricing.
Why it happened: The price evidence: the score was set on the $147 first-month figure, which we had recorded as a monthly rate. The record was corrected on 6 October (previous entry); the score is corrected now.
How we found out: Follow-up to the 6 October correction, which recorded $247 as the monthly rate and left the pricing score for a re-score on our pricing rubric.
What we changed: pricing 8.0 -> 5.5; total 8.30 -> 7.68. Wellorithm moves from #1 to #4 of 46. The re-score compares it only with clinics that use the same all-inclusive pricing, as our rubric requires.
Does this clinic pay us?: Wellorithm IS an affiliate partner: it was approved on our traffic source on 8 October 2026. We may earn a commission if you sign up through our link. This correction moves a partner DOWN, from #1 to #4, and the cause is the price evidence above ($147 first month, then $247), not the partnership. Commission is never an input to any score.

Wellorithm review

Our cost-per-month guide miscounted how many of the clinics it names pay us

Published 2026-10-08. Corrected 2026-10-08.

What we published: The guide said "12 of the 18 clinics named here pay us a commission", then "11 of the 18" after Enhance.MD was paused.
What was actually true: The guide names 17 clinics, not 18: Wellorithm's name had been removed from it earlier the same day. Of the 17, 10 paid us a commission that morning, then 9 after Enhance.MD and Trimi Health paused. It now says "9 of the 17".
Why it happened: We recounted after each partner change but kept counting a clinic the text no longer named.
How we found out: Recounting the named clinics from the article itself when Trimi Health paused its affiliate programme on 8 October 2026.
What we changed: The disclosure sentence now reads "9 of the 17 clinics named here pay us a commission". Trimi Health's affiliate programme is paused: its link is removed, and its score, rank and review are unchanged.
Does this clinic pay us?: Trimi Health WAS an affiliate partner until 8 October 2026, when it paused its programme; we earn nothing from it while the pause lasts. Enhance.MD is paused by us (its link loses our tracking ID). Wellorithm is a partner. None of these changes moves any score.

Trimi review Enhance.MD review Wellorithm review

Wellorithm's $147 is the first month only; from the second month it is $247

Published 2026-10-02. Corrected 2026-10-06.

What we published: Wellorithm's review and our rankings described it as "From $147/mo" and "Compounded semaglutide from $147/mo (+$100 off first month)", and showed $147 as its monthly price.
What was actually true: Wellorithm's semaglutide card says "first month $147" and "Second month and on. $247" (read 6 October 2026). $147 is a one-month entry price; the ongoing rate is $247 a month.
Why it happened: The $147 headline was recorded as a monthly rate, although our own pros line already described it as a first-month discount.
How we found out: A re-check of the articles scheduled for 7 to 13 October flagged that our live-price quote for Wellorithm ("Second month and on. $247") disagreed with the record's $147/mo; we re-read the card on 6 October 2026 to settle it.
What we changed: The record now carries $247 as Wellorithm's monthly rate and states the $147 first month separately, and the review text says "$147 for the first month, then $247/mo". Its pricing score (8.0, set on $147/mo) was not changed by this correction; it was re-scored on 8 October 2026, in the next entry.
Does this clinic pay us?: Not a partner when this correction was made: on 6 October 2026 Wellorithm's affiliate programme was pending on our traffic source, so there was no affiliate link and no commission. It became an affiliate partner on 8 October 2026; the pricing re-score that followed this correction is the next entry.

Wellorithm review

We credited WellMedr with brand-name Ozempic and Zepbound that its page never says it sells

Published 2026-09-17. Corrected 2026-10-03.

What we published: WellMedr's treatment score was 8.0 and its total 7.7/10, #6 in the ranking. The reasoning was that it "Offers BOTH compounded (semaglutide/tirzepatide) and FDA-approved brand-name (Ozempic, Zepbound)". Its review listed "brand-name Ozempic" and "brand-name Zepbound" among its treatments, a pro read "Both compounded and FDA-approved brand-name options on one platform", and its one-liner promised "brand-name Ozempic/Zepbound access".
What was actually true: Read on the rendered page on 2026-10-03 (wellmedr.com/pages/get-started-weight-loss): the cards say "Ozempic Starting at $1,399" with "Contains Semaglutide" and "Zepbound starting at $1,599" with "Contains Tirzepatide". Nowhere does the page say whether either is the brand-name product or a compounded version, and its safety notice says "welludoc offers compounded GLP-1 medications exclusively from licensed U.S. pharmacies." Brand access was never established. Without it, WellMedr offers two compounded molecules by injection, the profile we score 7.5 at HealthRX, Yucca Health, yourEra and SnagRx.
Why it happened: We carried WellMedr's treatment list over from our sister site, where it was written as "brand-name Ozempic" and "brand-name Zepbound". The page shows those names and a price, but never says the drug is the brand-name product, and we credited brand access without checking that it did.
How we found out: Re-reading the ten clinics that list Ozempic by name for our guide on getting Ozempic, to record what each price pays for.
What we changed: treatment 8.0 -> 7.5; total 7.7 -> 7.6. WellMedr moves from #6 to #7. Its treatments are recorded as "brand or compounded not stated", the brand pro and one-liner claim are removed, and its review now tells readers to ask which product they would receive. WellMedr is NOT an affiliate partner: its program is pending on our side and it has no affiliate link, so no commission is involved either way.
Does this clinic pay us?: Not a partner. Its affiliate program is pending on our side and it has no affiliate link, so no commission was involved either way.

Welludr (formerly Wellmedr) review

Oak's transparency score did not reflect its compounded-drug sameness claim

Published 2026-09-16. Corrected 2026-10-03.

What we published: Oak's transparency score was 7.0 and its total 7.73/10, #5 of 46.
What was actually true: Oak's weight-loss page (oaklovesyou.com/weightloss), read 2026-10-03, says: "Our compounded GLP-1 medications contain the same active ingredient (semaglutide) as brand-name drugs." and "Our compounded semaglutide uses the same active ingredient but is prepared by licensed compounding pharmacies at a significantly lower cost. Same science, fraction of the price." The page never says the compounded product is not FDA-approved. Our sameness-claim rule, adopted 2026-10-03 and applied to every clinic on all four of our sites, partner or not: when a compounded product is described as the same as an FDA-approved drug, or shown with the brand drug's trial results, and the same page does not say the compounded product is not FDA-approved, transparency is capped at 5.0. FDA's March 2026 warning letters to 30 telehealth companies cited "claims implying sameness with FDA-approved products".
Why it happened: The claim was on the clinic's own page, but until 2026-10-03 our transparency rubric did not weigh sameness claims at all, so the score never reflected it. The rule was added that day, applied to every clinic on all four of our sites, partner or not.
How we found out: A live audit of every clinic on all four of our sites on 2026-10-03, rendered in Chrome, run after we found this kind of claim on Synergy Rx's product page while writing our Ozempic guides.
What we changed: transparency 7.0 -> 5.0; total 7.73 -> 7.23; #5 -> #19 of 46. Oak IS an affiliate partner with an active link, so this correction moves a PARTNER DOWN. The commission plays no part in the score, in either direction. The review page now shows the cap and the quote.
Does this clinic pay us?: Partner, with an active affiliate link. This correction moved a partner down.

Oak review

Synergy Rx's transparency score did not reflect its compounded-drug sameness claim

Published 2026-09-16. Corrected 2026-10-03.

What we published: Synergy Rx's transparency score was 7.0 and its total 7.45/10, #14 of 46.
What was actually true: Synergy Rx's products page (synergyrx.co/products, WEIGHT LOSS tab), read 2026-10-03: the compounded semaglutide card says "Same active ingredient as Ozempic®* and Wegovy®*" and "15-18% average weight loss in clinical trials"; the compounded tirzepatide tablet card says "It has the same active ingredient as Mounjaro® and Zepbound®". The asterisks lead to no footnote, and the page never says the products are not FDA-approved. Our sameness-claim rule, adopted 2026-10-03 and applied to every clinic on all four of our sites, partner or not: when a compounded product is described as the same as an FDA-approved drug, or shown with the brand drug's trial results, and the same page does not say the compounded product is not FDA-approved, transparency is capped at 5.0. FDA's March 2026 warning letters to 30 telehealth companies cited "claims implying sameness with FDA-approved products".
Why it happened: The claim was on the clinic's own page, but until 2026-10-03 our transparency rubric did not weigh sameness claims at all, so the score never reflected it. The rule was added that day, applied to every clinic on all four of our sites, partner or not.
How we found out: A live audit of every clinic on all four of our sites on 2026-10-03, rendered in Chrome, run after we found this kind of claim on Synergy Rx's product page while writing our Ozempic guides.
What we changed: transparency 7.0 -> 5.0; total 7.45 -> 6.95; #14 -> #24 of 46. Synergy Rx was an affiliate partner until its program was paused on 2026-09-28; it has no active link and we earn nothing from it. The review page now shows the cap and the quote.
Does this clinic pay us?: Not a partner. Synergy Rx was one until its affiliate program was paused on 2026-09-28; it has no active link and we earn nothing from it.

Synergy Rx review

GobyMeds's transparency score did not reflect its compounded-drug sameness claim

Published 2026-10-01. Corrected 2026-10-03.

What we published: GobyMeds' transparency score was 5.5 and its total 6.45/10, #33 of 46.
What was actually true: GobyMeds' compounded semaglutide page (gobymeds.com/getting-started/compounded-semaglutide), read 2026-10-03, says "Semaglutide has demonstrated the ability to reduce body mass by up to 15%." with a footnote to a "68 week clinical trial of weekly Semaglutide injection with 1,961 participants", which is the brand drug's STEP 1 trial. The page does not say the compounded product is not FDA-approved; its separate legal pages do, but the reader of the claim never sees them. Our sameness-claim rule, adopted 2026-10-03 and applied to every clinic on all four of our sites, partner or not: when a compounded product is described as the same as an FDA-approved drug, or shown with the brand drug's trial results, and the same page does not say the compounded product is not FDA-approved, transparency is capped at 5.0. FDA's March 2026 warning letters to 30 telehealth companies cited "claims implying sameness with FDA-approved products".
Why it happened: The claim was on the clinic's own page, but until 2026-10-03 our transparency rubric did not weigh sameness claims at all, so the score never reflected it. The rule was added that day, applied to every clinic on all four of our sites, partner or not.
How we found out: A live audit of every clinic on all four of our sites on 2026-10-03, rendered in Chrome, run after we found this kind of claim on Synergy Rx's product page while writing our Ozempic guides.
What we changed: transparency 5.5 -> 5.0; total 6.45 -> 6.33; #33 -> #37 of 46. GobyMeds is NOT an affiliate partner. The review page now shows the cap and the quote.
Does this clinic pay us?: Not a partner.

GobyMeds